Ayaka Isogai

Dr. Ayaka Isogai

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
YEYuka Endo
Yuka Endo
AYAkiyo Yoshimura
Akiyo Yoshimura
MSMasataka Sawaki
Masataka Sawaki
MHMasaya Hattori
Masaya Hattori
KKKotani Kotani
Kotani Kotani
Hiroji IwataHiroji Iwata
Hiroji Iwata
Endo Y, et al. J Breast Cancer. 2022 Jul;25:e34. https://doi.org/10.4048/jbc.2022.25.e34

18 August 2022 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
NMNana Matsumoto
Nana Matsumoto
NKNaoto Kondo
Naoto Kondo
YWYumi Wanifuchi-Endo
Yumi Wanifuchi-Endo
TATomoko Asano
Tomoko Asano
THTomoka Hisada
Tomoka Hisada
TTTatsuya Toyama
Tatsuya Toyama
Background: Granulocyte colony-stimulating factor (G-CSF) is increasingly used to prevent chemotherapy-associated febrile neutropenia. Generally, aortitis is not considered a side effect of G-CSF and is thought to be extremely rare. Aortitis is an inflammation of the aorta and occurs mainly in connective tissue diseases (Takayasu arteritis, giant cell arteritis, etc.) and infectious diseases (bacterial endocarditis, syphilis, etc.). We report herein a rare case of G-CSF associated with aortitis in a woman with breast cancer. Case presentation: Here, we present a case involving a 63-year-old woman with luminal type stage IIa breast cancer. The patient’s treatment was initiated with docetaxel and cyclophosphamide, with pegfilgrastim (PEG-G) as support. After PEG-G administration on day 3, the patient developed an intermittent fever of up to 39.4 °C on day 10 and visited our outpatient clinic on day 13 with persistent high fever. Laboratory tests revealed a high neutrophil count (14,000/μL) and a high C-reactive protein (CRP) level (42.8 mg/dL) without any other abnormalities. Contrast-enhanced computed tomography scanning revealed soft tissue thickening with weak enhancement around the wall of the thoraco-abdominal aorta, aortic arch and left subclavian artery. The patient did not respond to antimicrobial agents. On the basis of these observations, the patient was diagnosed with PEG-G-induced aortitis, and her condition rapidly improved without corticosteroids. Conclusions: Clinicians should be aware of aortitis as a potential complication in patients undergoing G-CSF chemotherapy. In cases with persistent high fever after PEG-G administration, and in the absence of infection, aortitis should be suspected.

4 February 2026 in Surgical Oncology
Verified
Journal Article
Closed access
YNYuka Niwa
Yuka Niwa
MTMitsuo Terada
Mitsuo Terada
YWYumi Wanifuchi-Endo
Yumi Wanifuchi-Endo
TFTakashi Fujita
Takashi Fujita
TATomoko Asano
Tomoko Asano
TTTatsuya Toyama
Tatsuya Toyama

21 June 2023 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
AIAyaka Isogai
Ayaka Isogai
KKKotani Kotani
Kotani Kotani
MSMasataka Sawaki
Masataka Sawaki
MHMasaya Hattori
Masaya Hattori
AYAkiyo Yoshimura
Akiyo Yoshimura
Hiroji IwataHiroji Iwata
Hiroji Iwata
Background: With advances in breast cancer treatment, the importance of de-escalation therapy to reduce harm during the treatment of elderly patients has attracted attention in recent years. Certain patient populations are expected to have a superior response to anti-HER2 drugs, particularly those with human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. In this report, we describe our experience of dramatic anti-HER2 drug response in a patient who achieved pathological complete response (pCR) with a single dose of trastuzumab. Case presentation: An 88-year-old woman presented with a 2-cm palpable mass in the left breast. Vacuum-assisted breast biopsy, ultrasonography, and positron emission tomography–computed tomography revealed estrogen receptor-negative and HER2-positive, T1N0M0, stage I breast cancer. Mastectomy was scheduled within 2 months of the initial visit; however, the patient was anxious about the length of the waiting period and requested medication in the interim. Therefore, prior to surgery, one cycle of trastuzumab monotherapy was administered at the discretion of the attending physician. Postoperative pathology showed no remnant of invasive carcinoma and pCR with only a 0.2-mm ductal carcinoma in situ remnant. The patient refused further medication after surgery because of severe diarrhea after trastuzumab administration. Postoperative treatment was limited to follow-up, and no recurrence was observed at 1 year and 6 months postoperatively. Conclusion: This case suggests that trastuzumab monotherapy may be effective in certain patients with HER2-positive breast cancer. In the future, identifying patients who are more likely to respond to trastuzumab, as in this case, will allow for more options regarding de-escalation therapy without chemotherapy, particularly in elderly patients who are concerned about the side effects of chemotherapy.


1 January 2024 in The Breast Journal
Verified
Journal Article
Open access
NHNanae Horisawa
Nanae Horisawa
AYAkiyo Yoshimura
Akiyo Yoshimura
IOIsao Oze
Isao Oze
MSMasataka Sawaki
Masataka Sawaki
MHMasaya Hattori
Masaya Hattori
Hiroji IwataHiroji Iwata
Hiroji Iwata
Purpose. Breast cancer‐related lymphedema (LE) significantly impairs the patients’ quality of life. Axillary lymph node dissection (ALND) is a strong risk factor for LE in breast cancer surgery. In addition, postoperative administration of docetaxel (DTX) has been reported to be a risk factor for LE in patients who undergo ALND. Herein, we performed the risk of objective LE after ALND. Methods. Patients who visited the medical follow‐up clinic between 12 November 2018 and 11 January 2019 and at least one year postoperatively were eligible for this study. The risk factors for objective LE according to taxane‐containing regimen, radiation therapy, and body mass index and the effects of a taxane‐containing regimen followed by supraclavicular irradiation on LE were examined. Results. A total of 214 patients were included in this analysis, and objective LE was observed in 52 patients (24%). Univariate and multivariate analyses showed that only supraclavicular field irradiation was a statistically significant risk factor for objective LE. In addition, the sequential use of taxane‐containing regimens and supraclavicular RT was shown to be a more likely risk factor for LE than ALND alone. We also compared each taxane regimen with supraclavicular RT and found that DTX was more likely to be a risk factor for LE in cases of sequential use of supraclavicular RT than with ALND alone. However, when comparing DTX with supraclavicular RT and PTX with supraclavicular RT directly, there was no statistically significant difference in the risk of objective LE between the two groups. Conclusion. The risk for LE was more likely to be higher with the sequential use of taxane‐containing chemotherapy and supraclavicular field irradiation. Therefore, management of LE is important in these cases.